Related Experiment Video

Updated: Oct 4, 2026

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats
05:09

Long-Term Continuous Measurement of Renal Blood Flow in Conscious Rats

Published on: February 8, 2022

Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats

M Bak1, K Thomsen, A Flyvbjerg

  • 1Institute for Basic Psychiatric Research, Department of Biological Psychiatry, Aarhus University Hospital, Skovagervej, Risskov, Denmark. martinbak@dadlnet.dk

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|September 27, 2001
PubMed
Abstract

Insights

Chronic octreotide treatment prevents diabetes-induced renal hyperfiltration in rats by increasing afferent arteriolar resistance. This suggests potential for growth hormone/insulin-like growth factor inhibitors in managing diabetic kidney complications.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Growth hormone (GH) and insulin-like growth factors (IGFs) are implicated in early diabetic nephropathy, causing renal hypertrophy and hyperfiltration.
  • GH/IGF inhibitors, like somatostatin analogues (octreotide, lanreotide), are proposed to prevent long-term diabetic kidney complications.

Purpose of the Study:

  • To investigate the acute and chronic effects of octreotide on renal function in streptozotocin-induced diabetic rats.

Main Methods:

  • Conscious, non-fasted diabetic rats were administered octreotide.
  • Renal function parameters including effective renal plasma flow (ERPF), effective renal vascular resistance (ERVR), filtration fraction (FF), glomerular filtration rate (GFR), and absolute proximal tubular fluid reabsorption (APR) were measured.

Main Results:

  • Chronic octreotide (7 days) prevented diabetes-induced increases in FF, GFR, and APR, and normalized ERVR. Renal hypertrophy was partially inhibited.
  • Acute octreotide administration showed similar effects on ERPF and ERVR, but GFR remained unchanged and FF increased.

Conclusions:

  • Chronic octreotide administration effectively prevented diabetes-related renal hyperfiltration in rats.
  • The protective effect is likely mediated by increased afferent arteriolar resistance.

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes Insipidus II: Pathophysiology01:22

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...